August 8, 2022

Medical Trend

Medical News and Medical Resources

Denmark announced the suspension of Johnson & Johnson’s vaccine

Denmark announced the suspension of Johnson & Johnson’s COVID-19 vaccine

 

Denmark announced the suspension of Johnson & Johnson’s COVID-19 vaccine.  The Danish National Health Service issued a press release on May 03,  announcing that the COVID-19 vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, will be removed from the country’s vaccination plan.

According to the communiqué, based on the relevant international data and reports released last month and the expert panel’s assessment of Johnson & Johnson’s COVID-19 vaccine, the Danish National Health Service believes that “the benefits of vaccinating Johnson & Johnson’s vaccine are not greater than the risk of side effects.” The vaccine was removed from the national COVID-19 vaccination plan. When making this decision, the European Medicines Agency also considered the conclusion of the investigation on April 20 that the vaccination of Johnson & Johnson may be associated with the occurrence of thrombosis.

The communique also stated that the announcement of the official suspension of Johnson & Johnson’s vaccine does not mean that the vaccine will not be reactivated in the future, depending on the Danish epidemic situation and the supply of other vaccines.

On April 14, the Danish National Health Service announced that it would stop vaccinating the COVID-19 vaccine jointly developed by the British AstraZeneca Pharmaceutical Company and the University of Oxford for the same reason.

According to data released by the Danish National Serum Institute on May 3, more than 1.36 million people in Denmark have received at least one dose of the COVID-19 vaccine, accounting for about 23.4% of the total population.

 

Related news:

Canada suspends the first batch of Johnson & Johnson vaccines just received

In Toronto on May 1st, due to the discovery of hidden vaccine quality problems, the Canadian government decided to suspend the use of the first batch of Johnson & Johnson’s COVID-19 vaccine just received.

The Canadian Ministry of Health said on April 30 that it has learned that a drug substance produced by a pharmaceutical plant of the American emerging biotechnology company in Baltimore, Maryland, was used in the first batch of Johnson & Johnson vaccine received by Canada on April 28. The drug substance is the active ingredient required for the manufacture of vaccines.

Previously, US media disclosed at the end of March that the factory mistakenly mixed the raw materials of AstraZeneca vaccine with Johnson & Johnson vaccine, resulting in 15 million doses of Johnson & Johnson vaccine being contaminated and forced to be destroyed. At present, the US Food and Drug Administration has ordered the plant to stop the production of Johnson & Johnson vaccines.

The Canadian Ministry of Health stated that all vaccines imported by the country must meet the standards of quality, safety and efficacy before they are allowed to be distributed and used. The Canadian Founder is cooperating with Johnson & Johnson and the US Food and Drug Administration to obtain the complete information needed for the evaluation.

The Canadian Ministry of Health also stated that it still believes that the 1.5 million doses of AstraZeneca vaccine produced by the plant and imported into Canada meet the quality requirements.

The Canadian government approved the COVID-19 vaccine produced by Johnson & Johnson in early March. This is also the first single-dose COVID-19 vaccine approved for marketing in Canada. In addition, the country has currently approved three vaccines from Pfizer, Moderna and AstraZeneca. Canada received its first batch of 300,000 doses of Johnson & Johnson vaccine on April 28.

As of the evening of April 30, the cumulative number of reported cases in Canada has exceeded 1.2 million, or about 1.2194 million; about 1.1119 million recovered, 24,219 deaths, and 83,319 active cases. The country has received about 13.42 million doses of vaccine; about 1.013 million people completed two doses, accounting for 2.66% of the total population.

 

 

 

(source:internet, reference only)


Disclaimer of medicaltrend.org